Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019005756) ANTI-MERTK AGONISTIC ANTIBODY-DRUG CONJUGATES AND USES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/005756 International Application No.: PCT/US2018/039445
Publication Date: 03.01.2019 International Filing Date: 26.06.2018
IPC:
A61K 39/395 (2006.01) ,A61K 45/00 (2006.01) ,A61K 45/06 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants:
THE ROCKEFELLER UNIVERSITY [US/US]; 1230 York Avenue New York, NY 10065, US
RGENIX, INC. [US/US]; 310 E. 67th Street New York, NY 10065, US
Inventors:
TAVAZOIE, Sohail; US
TAVAZOIE, Masoud; US
Agent:
NORTON, Gerard, P.; US
BUTCH, Peter, J.; US
BARRISON, Flynn; US
HAO, Jianming; US
JOE, Chen; US
Priority Data:
62/525,99328.06.2017US
Title (EN) ANTI-MERTK AGONISTIC ANTIBODY-DRUG CONJUGATES AND USES THEREOF
(FR) CONJUGUÉS ANTICORPS AGONISTE ANTI-MERTK-MÉDICAMENT
Abstract:
(EN) The present disclosure provides antibody-drug conjugates comprising (i) antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates, wherein the antibodies contained in the antibody-drug conjugates agonize MERTK signaling of endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody-drug conjugate that comprises (i) an antibody that specifically binds to MERTK and agonizes MERTK signaling of endothelial cells, and (ii) a cytotoxic agent conjugated directly to the antibody or conjugated to the antibody via a linker.
(FR) La présente invention concerne des conjugués anticorps-médicament comprenant (i) des anticorps qui se lient spécifiquement à la tyrosine kinase mer (MERTK) (par exemple, la MERTK humaine, ou la MERTK humaine et murine), et (ii) des agents cytotoxiques conjugués directement aux anticorps ou conjugués aux anticorps par l'intermédiaire de lieurs, et des compositions comprenant de tels conjugués anticorps-médicament, les anticorps contenus dans les conjugués anticorps-médicament ayant un effet agoniste sur la signalisation MERTK des cellules endothéliales. La présente invention concerne également des procédés de traitement du cancer, par l'administration d'un conjugué anticorps-médicament qui comprend (i) un anticorps qui se lie spécifiquement à la MERTK et a un effet agoniste sur la signalisation MERTK des cellules endothéliales, et (ii) un agent cytotoxique conjugué directement à l'anticorps ou conjugué à l'anticorps par l'intermédiaire d'un lieur.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)